Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

AMXX
Sort by: Date|Relevance

Neovasc Shares Climb 80% Upon FDA Premarket Approval Filing for Refractory Angina Device

Shares of specialty cardiovascular medical device company Neovasc Inc. opened more than 100% higher after the firm reported that it submitted a Premarket Approval application to the FDA for its Neovasc Reducer device for use in the treatment of refractory angina. This...
Streetwise Reports | January 3, 2020 |

What to do if you like QE3 but stocks make you nervous

QE2 in 2010 and ‘Operation Twist’ in 2011 recovered the stock market from double-digit corrections that were underway at the time, and rescued investors from their extreme bearish sentiment each time. QE3 is underway and many are convinced that&CloseCurlyQu...
Sy Harding | October 28, 2012 |

The New Cannabis & CBD Therapy for PTSD

This podcast is part of our StockTalk Cannabis Sector CEO interview series, and our mission going forward is to help listeners and investors understand more about investment opportunities in the public cannabis marketplace. There are around eight million people in the U...
Stockhouse Media | November 6, 2019 |

Torrid Advances in Gold ETFs Warrant Caution

Michael Ballanger explains how he is reacting to the advances in the gold ETFs. Given the torrid advance in gold (GLD [SPDR Gold Shares]) and the leveraged miner ETFs (NUGT [Direxion Daily Gold Miners Index Bull 3x]/JNUG [Direxion Daily Junior Gold Miners In...
Streetwise Reports | June 5, 2019 |

Near-Term Risk in Gold is Increasing

Last week was another strong one for the precious metals sector. Gold gained a whopping $51/oz or 3.5%. The gold stocks (GDX, GDXJ) advanced by roughly 6%. Silver gained 4%. Momentum in the sector began to build once Gold surpassed resistance at $1420-$1425/oz. We had ...
Jordan Roy-Byrne, CMT | August 14, 2019 |

Correction in Gold Stocks Continues

Several weeks ago both Gold and gold stocks hit major resistance after strong but extended moves. A correction or pause was to be expected. Clearly, we can now say, the sector is in correction mode. Corrections tend to have three legs: a simple down up down or A-B-C patter...
Jordan Roy-Byrne, CMT | October 1, 2019 |

Gold's getting its lustre back

Gold has been almost as volatile as the stock market since August. After becoming overheated in July and early August, it plunged $340 an ounce to its low of $1,592 in late September. In one brief period in September it collapsed $214 an ounce in just four days. Not surpri...
Sy Harding | October 28, 2012 |

After An Extremely Rare Move In Bonds, How Have Stocks And Bonds Performed In The Past?

LEARNING FROM HISTORICAL MARKET FACTS When investors are concerned about future economic outcomes, they often migrate toward more defensive-oriented long-term U.S. Treasury bonds (TLT). The recent surge in demand for defensive bonds caused an extremely rare and extended loo...
Chris Ciovacco | June 11, 2019 |

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher

Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. Yesterday afternoon, Dermira Inc. (DERM:NASDAQ) , a biopharmaceu...
Streetwise Reports | October 21, 2019 |

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug

Shares of Kiniksa Pharmaceuticals opened nearly 30% higher today after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. This morning, Hamilton, Bermuda based biopharmaceutical company ...
Streetwise Reports | November 21, 2019 |
1 2 3 4 5 6 7 8 9 10 ...